Clinical trials: Fat; Liver
Non Alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class of anti-diabetic agents that cause weight…
- Trial name
- E-LIFT (NCT02686476)
- Testing
- Empagliflozin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Non-alcoholic Fatty Liver Disease
Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children
The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with non-alcoholic fatty liver disease.
- Trial name
- NCT01547910
- Testing
- Fish Oil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Piotr Socha
Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight
Hepatoprotective Measures for Children at High Risk of NAFLD
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure.
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
- Trial name
- NCT06918080
- Testing
- Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Non Alcoholic Steatohepatitis
Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.
The aims of this study are as follows: To compare the role of alternate-day fasting over standard medical management alone to reverse NASH.
- Trial name
- NCT06676813
- Testing
- Alternate day fasting
- Where
- India
- Volunteers
- 72 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Fatty Liver
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by diabetes and obesity, and is becoming more common.
- Trial name
- NCT01766960
- Testing
- High fat meal, Morphine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Nash
Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.
- Trial name
- NCT01269320
- Testing
- Femarelle
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Diabetes Mellitus, Diabetes Complications
Screening Patients With Diabetes Mellitus for the Presence of Skin Disorder of Scleredema
Scleredema is a scleroderma-like skin disorder appearing in 2.5-14% among patients with type 1 or 2 diabetes mellitus. This is a single centre study to screen consecutive patients with diabetes mellitus for the presence of…
- Conditions
- Diabetes Mellitus, Diabetes Complications, Scleroderma-Like Changes, Scleredema Adultorum
- Trial name
- NCT04335396
- Where
- Hungary
- Volunteers
- 150 people
- Sponsor
- University of Pecs
Non-alcoholic Steatohepatitis, Fibrosis
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist.
- Conditions
- Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
- Trial name
- ENCORE-NF (NCT02686762)
- Testing
- Emricasan (5 mg), Emricasan (50 mg)
- Where
- 103 sites in United States, Germany and 1 more
- Volunteers
- 318 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Nonalcoholic Steatohepatitis
Norursodeoxycholic Acid vs. Placebo in NASH
This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral…
- Trial name
- NCT05083390
- Testing
- norUrsodeoxycholic acid
- Where
- Austria
- Volunteers
- 363 people
- Sponsor
- Dr. Falk Pharma GmbH
NAFLD
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomized, single blind study to determine whether AXA1125 or AXA1957, novel compositions of amino acids, are safe and well tolerated.
- Trial name
- NCT04073368
- Testing
- AXA1957, AXA1125
- Where
- 18 sites in United States
- Volunteers
- 112 people
- Sponsor
- Axcella Health, Inc
Non-Alcoholic Fatty Liver Disease
Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
The purpose of the study is to examine the effects of modified time-restricted feeding and conventional dietary approaches in motivated obese fatty liver patients on biochemical markers, imaging studies, and anthropometric…
- Trial name
- NCT03848390
- Testing
- Conventional diet, Modified Time-restricted Feeding, Physical activity
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Adiposity, Fatty Liver
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic…
- Conditions
- Adiposity, Fatty Liver, Alcohol Use Disorder
- Trial name
- GLP-1 RA (NCT06546384)
- Testing
- Semaglutide, Weight reduction recommendations (nutritional and exercise)
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
NON-ALCOHOLIC STEATOHEPATITIS
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06054815
- Testing
- DA-1241, Sitagliptin
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
HBV, NASH - Nonalcoholic Steatohepatitis
Mechanism of DCs Dysfunction in Chronic HBV Infection
This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their…
- Trial name
- HepatoDC (NCT03753308)
- Testing
- Blood Sampling, Liver biopsy
- Where
- France
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and…
- Trial name
- NCT06256289
- Testing
- Canagliflozin 100mg Tab, Metformin Hydrochloride
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ping Li,MD
NASH - Nonalcoholic Steatohepatitis
Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement
The aim of this bicentre, prospective, placebo-controlled, double-blind, randomized, interventional study is to assess for the first time the effects of a Combo with probiotics and dietary supplements compared to placebo for…
- Trial name
- ICAN (NCT04781933)
- Testing
- Treatment with Combo
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Mativa-Tech SA
Prediabetes, Diabetes Mellitus Type 2
Diabetes Nutrition Algorithm - Prediabetes
Prediabetes, defined by either impaired fasting glucose and/or impaired glucose tolerance, is a known high-risk condition predisposing to future diabetes mellitus type 2.
- Conditions
- Prediabetes, Diabetes Mellitus Type 2, Obesity, NAFLD
- Trial name
- DiNA-P (NCT02609243)
- Testing
- dietary consulting
- Where
- 2 sites in Germany
- Volunteers
- 250 people
- Sponsor
- German Institute of Human Nutrition
Non-alcoholic Fatty Liver Disease
Quantitative Detection Efficiency of UDFF for Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting more than 25 % of the population globally.
- Trial name
- UDFF (NCT05802199)
- Testing
- Hepatic fat fraction and hepatic fibrosis
- Where
- 14 sites in China, Switzerland
- Volunteers
- 300 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Liver Fibrosis
Development of a Novel Biomarker for Liver Fibrosis
The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
- Trial name
- NCT02348814
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Probiotics in the Treatment of NAFLD
Evaluate the effect of supplementation of probiotics on liver changes (histological and enzymatic), lipid profile and gut microbiota of patients with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, Nonalcoholic, NAFLD
- Trial name
- NCT02764047
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Federal University of Health Science of Porto Alegre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.